Examining drug interactions in older adults living with HIV
Official title: Variation in Drug Interactions in People With HIV (PLWH) Aged 60 Years and Older on Stable Antiretroviral Therapy Making a Switch to Bictegravir/Tenofovir Alafenamide/Emtricitabine
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06717581 · Data updated 2026-11-12
This study looks at how different medications interact in older adults with HIV to see if we can improve their treatment plans.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Status | Recruiting |
| Started | October 11, 2024 |
| Main results expected | April 11, 2025 |
| Study ends | October 11, 2025 |
| Registry record updated | December 5, 2024 |
| Trial ID | NCT06717581 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals aged over 60 who are living with HIV and are receiving drug therapy for non-infectious comorbidities.
✕Probably not a fit
Patients with evidence of viral resistance to integrase inhibitors or those suffering from severe acute infectious diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort study focuses on individuals aged 60 and older living with HIV who are on stable antiretroviral therapy. It aims to evaluate the variations in clinically significant drug interactions between antiretroviral medications and other treatments for comorbidities commonly found in this age group. The study will analyze data retrospectively from a single center to understand the impact of multiple drug therapies on this population. The findings could help in optimizing treatment regimens for older adults with HIV and their associated health conditions.
Why it matters
Potential benefit: If successful, this study could lead to improved management of drug interactions, enhancing the safety and efficacy of treatments for older adults living with HIV.
How similar studies have gone: Other studies have indicated the importance of understanding drug interactions in older populations, but this specific focus on older adults with HIV and their unique comorbidities is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 60 years * Non-infectious comorbidities receiving drug therapy * Receiving BIC/TAF/FTC therapy at the time of of enrollment Exclusion Criteria: * Genotypic resistance testing that present or past evidence of viral resistance to the integrase inhibitor class, to emtricitabine or to tenofovir * Severe acute infectious disease
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy Recruiting
Study contacts
- Principal investigator: Leonardo Calza, Medicine — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Leonardo Calza, Medicine
- Email: leonardo.calza@unibo.it
- Phone: +390512143353
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How environment and biology together predict health, aging, and death
Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.
-
100-Year Human Aging and Longevity Tracking Program
This project will follow adults over their lifetimes to see if repeated health tests can predict lifespan, causes of death, serious disease, and loss of function.
-
Lowering blood pressure by adding stair climbing to brisk walking
We will test whether adding short daily stair climbing to a brisk-walking program lowers systolic blood pressure in adults 35 and older who have high blood pressure, are overweight, and are not regularly active.
-
Collection of biospecimens for cardiovascular and metabolic research
This study is collecting blood, urine, stool, and heart tissue samples from people with and without heart and metabolic diseases to help researchers learn more about these conditions and improve treatments.
-
Evaluating a new CAR-T cell therapy for relapsed/refractory multiple myeloma
This study is testing a new CAR-T cell therapy called OriCAR-017 to see if it can help people with relapsed or refractory multiple myeloma feel better and improve their treatment outcomes.
-
Understanding chronic kidney disease in Sub-Saharan Africa
This study is trying to understand how common chronic kidney disease is in Sub-Saharan Africa and what factors might be causing it by looking at the health and lifestyle of adults in the Bagamoyo district.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.